echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Blockbuster SGLT2 inhibitors are eligible for FDA priority review, which is expected to benefit two types of heart failure patients

    Blockbuster SGLT2 inhibitors are eligible for FDA priority review, which is expected to benefit two types of heart failure patients

    • Last Update: 2021-12-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, Eli Lilly and Boehringer Ingelheim jointly announced that the U.


    Enpagliflozin is a highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that is taken orally once a day.


    ▲The primary and critical secondary endpoint data of the EMPEROR-Preserved trial (picture source: reference [2])

    This supplementary new drug application is based on the positive results of the Phase 3 clinical trial EMPEROR-Preserved


    Reference materials:

    [1] US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction.


    [2] Anker et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.